ASX Share rice
Fri 14 Aug 2020 - 08:08:pm (Sydney)

AFP Share Price

AFT PHARMACEUTICALS LIMITEDAFPPharmaceuticals, Biotechnology & Life Sciences

AFP Company Information

Name:

AFT Pharmaceuticals Limited

Sector:

Healthcare

Industry:

Drug Manufacturers—Specialty & Generic

Address:

129 Hurstmere Road Auckland New Zealand 0622

Phone:

64 9 488 0232

Full Time Employees:

86

Founder, CEO, MD & Exec. Director:

Dr. Hartley Atkinson

Chief of Staff & Exec. Director:

Ms. Marree Atkinson

CFO & Company Sec.:

Mr. Malcolm Tubby B.A., BA(Hon's), ICAEW, ICANZ

Group Marketing Mang.:

Mr. Murray Keith

Head of Drug Devel.:

Ms. Ioana Stanescu

Company Overview:

AFT Pharmaceuticals Limited develops, licenses, and sells pharmaceutical products in New Zealand, Australia, Southeast Asia, and internationally. The company offers approximately 130 prescription and non-prescription products for use in the areas of allergy, eye care, first aid, fungal, pain management, and skin care, as well as supplements. It is also involved in the distribution of pharmaceuticals. The company was founded in 1997 and is headquartered in Auckland, New Zealand.

AFP Share Price Information

Shares Issued:

103.17M

Market Capitalisation:

$438.46M

Profit Margin:

0.1202

Return On Assets (TTM):

$0.10

Return On Equity (TTM):

$1.14

Quarterly Revenue Growth (YOY):

0.256

Gross Profit(TTM):

$48.27M

QuarterlyEarnings Growth(YOY):

1.041

AFP CashFlow Statement

CashFlow Date:

2020-03-31

Investments:

$-6,562,000

Change To Liabilities:

$5.88M

Total Cashflow From Investing Activities:

$-6,562,000

Net Borrowings:

$-2,655,000

Net Income:

$12.69M

Total Cash From Operating Activities:

$14.88M

Dividends Paid:

$-566,000

Capital Expenditures:

$6.56M

AFP Income Statement

Income Date:

2020-03-31

Income Before Tax:

$12.88M

Net Income:

$12.69M

Gross Profit:

$47.91M

Operating Income:

$10.61M

Other Operating Expenses:

$-535,000

Interest Expense:

$8.05M

Income Tax Expense:

$185K

Total Revenue:

$105.24M

Cost Of Revenue:

$57.33M

AFP Balance Sheet

Balance Sheet Date:

2020-03-31

Intangible Assets:

$26.98M

Total Liabilities:

$69.80M

Total Stockholder Equity:

$17.26M

Total Assets:

$87.05M

Common Stock:

$57.06M

Retained Earnings:

$-49,275,000

Other Assets:

$12.23M

Cash:

$6.12M

Total Current Liabilities:

$25.10M

Property - Plant & Equipment:

$4.03M

Net Tangible Assets:

$-9,000,000

Total Current Assets:

$55.34M

Long-Term Debt:

$41.20M

Net Receivables:

$26.86M

Short-Term Investments:

$31.72M

Inventory:

$22.73M

Accounts Payable:

$8.62M

Non Currrent Assets (Other):

$31.72M

Short-Term Investments:

$31.72

Non Current Liabilities Total:

$44.70M

AFP Share Price History

AFP News

13 Jul, 2020
The big shareholder groups in AFT Pharmaceuticals Limited (NZSE:AFT) have power over the company. Institutions often...
24 May, 2020
AFT Pharmaceuticals Limited (NZSE:AFT) defied analyst predictions to release its full-year results, which were ahead...
08 May, 2020
By buying an index fund, you can roughly match the market return with ease. But many of us dare to dream of bigger...
08 Feb, 2020
Hartley Atkinson became the CEO of AFT Pharmaceuticals Limited (NZSE:AFT) in 1997. This report will, first, examine...
25 Nov, 2019
BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has signed an exclusive License and Supply Agreement (“the Agreement”) with AFT Pharmaceuticals (“AFT”, NSX: AFT, ASX: AFP) for a portfolio of new pain management products for the Canadian market. Health Canada has recently approved the first form of Combogesic® and BioSyent Pharma Inc. intends to launch the product in 2020. Under the Agreement, BioSyent Pharma Inc. also has rights to additional forms of Combogesic® - some of which have been approved in other countries and for which it intends to seek approval in Canada.
10 Nov, 2019
Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right...